Echocardiogram — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

An echocardiogram (echo) is a non-invasive or minimally invasive cardiac imaging study that uses high-frequency ultrasound waves to produce real-time images and Doppler measurements of the heart's structure and function. Unlike chest X-ray and ECG, which provide indirect information, echocardiography directly visualises cardiac chambers, valves, myocardial wall motion, great vessels, and pericardium in real time, allowing both anatomical and haemodynamic assessment in a single examination. The standard technique is transthoracic echocardiography (TTE), in which a handheld transducer is placed on the chest wall in multiple standardised positions to acquire 2D, 3D, M-mode, colour Doppler, pulsed-wave Doppler, continuous-wave Doppler, and tissue Doppler images. Transoesophageal echocardiography (TOE/TEE), in which a miniature transducer on a flexible endoscope is positioned in the oesophagus behind the heart, provides superior image quality for posterior cardiac structures including the mitral valve, left atrial appendage, atrial septum, and aortic root. Stress echocardiography adds exercise or pharmacological (dobutamine) stress to detect regional wall motion abnormalities indicating reversible ischaemia. Contrast echocardiography uses intravenous microbubble agents to enhance endocardial border definition and assess myocardial perfusion. Over 2 million echocardiograms are performed annually in England.

Echocardiography is the most widely ordered cardiac investigation in clinical practice and is indicated across an extensive range of conditions. Chest pain evaluation: distinguishing myocardial infarction with regional wall motion abnormality from pericarditis, aortic dissection, or pulmonary embolism with right heart strain. Dyspnoea assessment: quantifying left ventricular ejection fraction (LVEF) to diagnose heart failure with reduced (HFrEF, LVEF <40%) or preserved (HFpEF, LVEF ≥50%) function. Heart murmur evaluation: precisely characterising valvular stenosis (aortic, mitral) or regurgitation severity to guide timing of valve repair or replacement. Atrial fibrillation: assessing left atrial size and function, ruling out thrombus before cardioversion (TOE). Infectious endocarditis: detecting vegetations, perivalvular abscess, and valve perforation. Pericardial disease: diagnosing tamponade, effusion, and constrictive pericarditis. Congenital heart disease: detecting and quantifying ASDs, VSDs, patent ductus arteriosus. Aortic disease: measuring aortic root and ascending aorta dimensions. Chemotherapy monitoring: serial assessment of LVEF in patients receiving cardiotoxic agents. Post-cardiac surgery follow-up: valve prosthesis assessment.

For transthoracic echocardiography (TTE), no preparation is required. The patient lies on a tilt-table couch, typically in the left lateral decubitus position. Electrode stickers record a simultaneous ECG trace. Ultrasound gel is applied to the chest to eliminate air between the transducer and skin. The echocardiographer acquires standardised views from the parasternal (left edge of sternum), apical (cardiac apex), subcostal (below the ribcage), and suprasternal notch windows over 30–45 minutes. Each view provides specific anatomical information: parasternal long-axis for mitral and aortic valves; apical four-chamber for all chambers and AV valves; apical five-chamber adding the aortic outflow; subcostal for inferior vena cava and pericardium. The LVEF is measured by the biplane Simpson method from apical views; valve gradients and areas by continuous-wave Doppler. For TOE, the patient fasts for 4–6 hours, intravenous sedation (midazolam ± fentanyl) and throat anaesthetic spray are given, and the echoendoscope is passed into the oesophagus under monitoring, acquiring multiplane images at multiple probe depths. Reporting is completed by a cardiologist. Results are typically available immediately or within 24 hours. Stress echocardiography (exercise or dobutamine pharmacological stress) adds dynamic assessment of wall motion abnormalities at peak heart rate, detecting inducible ischaemia with sensitivity 80–85% and specificity 85–90% for coronary artery disease.

Echocardiography accurately measures left ventricular ejection fraction (normal 55–70%) with a test-retest variability of approximately 5% in experienced hands, making it the gold-standard clinical tool for heart failure monitoring. Colour Doppler identifies valvular regurgitation jets; continuous-wave Doppler quantifies transvalvular gradients and valve area (AVA) with accuracy sufficient to guide surgical decisions for aortic stenosis (AHA/ACC criteria: severe AVA <1.0 cm², mean gradient >40 mmHg). TOE detects left atrial appendage thrombus with sensitivity of 95–100% before electrical cardioversion, significantly superior to TTE. Stress echocardiography has sensitivity of 80–88% and specificity of 83–88% for significant coronary artery disease — superior to exercise ECG alone. Contrast echo improves LVEF measurement accuracy in patients with technically limited images. Echocardiography directly informs timing of valve surgery, selection of TAVI versus surgical AVR, selection of percutaneous mitral valve repair, and implantable cardioverter-defibrillator implantation in low LVEF patients. Overall detection sensitivity for major cardiac pathology exceeds 85–95% for most conditions.

Transthoracic echocardiography (TTE) is completely safe with no radiation and no known risks from diagnostic ultrasound at standard output levels. The only limitation is technically limited image quality (obesity, emphysema, chest wall deformity) — addressed by contrast agents or alternative modalities. Contrast echocardiography using microbubble agents (SonoVue, Definity) carries a very low risk of hypersensitivity reactions (approximately 1 in 10,000), with rare anaphylaxis. It is contraindicated in right-to-left intracardiac shunts. Transoesophageal echocardiography (TOE) is a semi-invasive procedure with a small but definite risk profile. Transient throat soreness and dysphagia from the probe passage affects the majority of patients and resolves within 24 hours. Oesophageal injury including perforation (Boerhaave syndrome) is very rare (<1 in 10,000) but potentially life-threatening. Sedation-related respiratory depression is managed with resuscitation equipment and personnel present throughout. Oxygen desaturation and aspiration risk mean the patient must fast adequately and be monitored throughout. TOE is contraindicated in oesophageal stricture, varices, recent oesophageal or gastric surgery, and uncooperative unsedated patients.

Transthoracic echocardiography requires no recovery — patients may drive, eat, drink, and resume all activities immediately after the scan. The ultrasound gel is wiped from the skin; no wound care is needed. Results are reported by the echocardiographer and communicated by the ordering physician, typically within 24–48 hours unless urgent same-day review is required. After TOE, patients are monitored in a recovery area for 1–2 hours until sedation has adequately worn off, assessed by a validated sedation scoring system before discharge. Patients are advised not to drive or operate machinery for 12–24 hours after sedation and should be accompanied home. A light meal and fluids can be resumed when the throat sensation has returned to normal, approximately 1–2 hours after the procedure. Mild throat discomfort is managed with lozenges or warm drinks. Patients should seek urgent assessment if they develop severe chest pain, difficulty swallowing, or fever after TOE — rare symptoms that may indicate oesophageal injury. No specific follow-up investigation is required after uncomplicated echocardiography beyond the planned cardiology consultation to discuss findings.